Interventional Radiology, Radiation Technician, Laboratory Technician, Oncology Nursing. Merck Foundation through its Merck Foundation Cancer Access Program has provided 194 scholarships of Oncology ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

With Mayne Pharma subject to a $670 million takeover offer, investor attention turns to who might be acquired next. ... Read More The post Biocurious: With Mayne Pharmaceuticals under takeover offer, ...

Interventional Radiology, Radiation Technician, Laboratory Technician, Oncology Nursing. Merck Foundation through its Merck Foundation Cancer Access Program has provided 194 scholarships of Oncology ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Merck & Co... We recently published a list of the 11 Best Pharma Stocks to Buy According ...